phone icon(716) 674-6030 fax icon(716) 674-6052
bill pay iconPay Your Bill
Receive our Health e-Newsletter
  Home  
  Our Team  
  Patient Info  
  Services  
   
  Patient Info  

News for Healthier Living

First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases

Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month clinical trial, named DAPA-PD, for the treatment of Parkinson's disease (PD).

March 24, 2026


April 4 2026

April 3 2026

April 2 2026

April 1 2026

March 31 2026

March 30 2026

March 29 2026

March 28 2026

March 27 2026

March 26 2026

March 25 2026

March 24 2026

March 23 2026

March 22 2026

March 21 2026